In clinical applications, the combined detection of HIF1A and PDIA3 expression levels in blood or saliva samples may enhance the diagnostic capability for OSA: an increase in HIF1A may indicate acute hypoxic events, while sustained high expression of PDIA3 may reflect chronic pathological damage. This evidence concerns the gene HIF1A and obstructive sleep apnea syndrome.